Polycyclo Ring System Patents (Class 514/510)
-
Publication number: 20120022156Abstract: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.Type: ApplicationFiled: February 12, 2010Publication date: January 26, 2012Applicant: REATA PHARMACEUTICALS, INC.Inventors: Jiang Zhang, Colin J. Meyer
-
Publication number: 20120015960Abstract: Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and colon cancer, of which diagnosis or treatment is not easy.Type: ApplicationFiled: November 23, 2009Publication date: January 19, 2012Applicants: The Industry & Academic Cooperation in Chungnam National University, Pusan National University Industry-University Cooperation FoundationInventors: Bum Joon Park, Nam Chul Ha, Sun Hye Lee, Gyu Yong Song, Jee Hyun Lee
-
Publication number: 20120010159Abstract: The present invention is directed to compositions and methods for pain management, and for treating inflammation or an inflammation-associated disorder in a subject comprising administering to the subject a therapeutically effective amount of a COX-2 inhibitor and a therapeutically effective amount of a prostacyclin analog, such as treprostinil, a pharmaceutically acceptable salt thereof, or a treprostinil derivative described herein.Type: ApplicationFiled: July 5, 2011Publication date: January 12, 2012Inventors: Martine Rothblatt, Martin Auster
-
Publication number: 20120010284Abstract: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.Type: ApplicationFiled: September 19, 2011Publication date: January 12, 2012Applicant: BEZWADA BIOMEDICAL, LLCInventor: Rao S. Bezwada
-
Publication number: 20120004232Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: September 8, 2011Publication date: January 5, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari SAKAGAMI, Hiroshi OHTA, Atsuro NAKAZATO
-
Patent number: 8088823Abstract: A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.Type: GrantFiled: June 13, 2007Date of Patent: January 3, 2012Assignee: Nabriva Therapeutics AGInventors: Gerd Ascher, Heinz Berner, Rosemarie Mang
-
Patent number: 8088824Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.Type: GrantFiled: August 13, 2008Date of Patent: January 3, 2012Assignee: Reata Pharmaceuticals Inc.Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
-
Publication number: 20110312985Abstract: The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.Type: ApplicationFiled: October 7, 2009Publication date: December 22, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Yaakov Nahmias, Martin L. Yarmush, Raymond T. Chung
-
Publication number: 20110311594Abstract: The present invention provides a controlled release pharmaceutical composition which exhibits reduced food effect.Type: ApplicationFiled: June 21, 2011Publication date: December 22, 2011Inventors: Shou-Chiung Chen, Shao-Ming Lee, Chaur-Ming Jan
-
Publication number: 20110312875Abstract: The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.Type: ApplicationFiled: August 2, 2011Publication date: December 22, 2011Applicant: UNIVERSITY OF WOLLONGONGInventors: Timothy Patrick Boyle, John Barnard Bremner, Zinka Brkic, Jonathan Alan Victor Coates, Neal Kevin Dalton, John Deadman, Paul Anthony Keller, Jody Morgan, Stephen Geoffrey Pyne, David Ian Rhodes, Mark James Robertson
-
Publication number: 20110311503Abstract: The novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) are very suitable for control of animal pests such as insects and/or unwanted acarids.Type: ApplicationFiled: June 16, 2011Publication date: December 22, 2011Applicant: BAYER CROPSCIENCE AGInventors: Christian FUNKE, Heike HUNGENBERG, Rüdiger FISCHER
-
Publication number: 20110301179Abstract: A compound (particularly useful for inhibiting cancer) according to formula I: or a pharmaceutically acceptable salt thereof, wherein: x is 0 or 1; R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl; R7 is H, alkyl, alkyl amino, aminoacyl, hydroxyacyl, heteroaryl, heterocycloalkyl, alkyl heteroaryl or alkyl heterocycloalkyl; R8 is H or alkyl; A is O or N; and Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, provided that if R7 is H then Ar is aryl substituted with alkyl amino.Type: ApplicationFiled: October 21, 2009Publication date: December 8, 2011Inventors: Xiangshu Xiao, Bingbing Li
-
Publication number: 20110294841Abstract: The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins.Type: ApplicationFiled: June 15, 2011Publication date: December 1, 2011Inventors: Hector GUZMAN, Örn ALMARSSON, Julius REMENAR
-
Publication number: 20110294830Abstract: The present invention provides a nitrogen-containing compound represented by formula (I1) (in formula (I1), R0 represents a nitro group or the like, Z represents an optionally substituted aryl group or the like, R3 represents a hydrogen atom or the like, Y represents a nitro group or the like, n represents an integer of 0 to 3, D represents an optionally substituted 5-membered to 8-membered hydrocarbon ring group or heterocyclic group having or not having a substituent other than substituent X, X represents a group represented by formula (II-1) (in formula (II-1), R1 and R2 respectively and independently represent a hydrogen atom or the like), A represents a carbon atom or the like, n1 represents an integer of 0 to 2) or a salt thereof, and an insecticide, miticide, sanitary insect pest control agent, or harmful organism control agent including as an active ingredient thereof the nitrogen-containing compound or the salt thereof.Type: ApplicationFiled: February 5, 2010Publication date: December 1, 2011Applicant: Nippon Soda Co., Ltd.Inventors: Jyun Iwata, Masahiro Kawaguchi, Akiko Mizui
-
Patent number: 8067394Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: GrantFiled: May 10, 2010Date of Patent: November 29, 2011Assignee: Trustees of Dartmouth CollegeInventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby
-
Publication number: 20110287112Abstract: A prostate cancer progression inhibitor comprises 4-(4-cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid, a salt thereof, a solvate thereof, or a prodrug thereof. 4-(4-Cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid is useful as a prostate cancer progression inhibitor because this butyric acid has, for example, a growth inhibiting effect and a hormone responsiveness recovering effect on prostate cancer that has acquired hormone resistance.Type: ApplicationFiled: January 29, 2010Publication date: November 24, 2011Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO UNIVERSITYInventors: Osamu Ogawa, Gozoh Tsujimoto, Eijiro Nakamura, Tomomi Kamba, Yosuke Shimizu, Naoki Terada, Toshiya Kanaji, Takayuki Maruyama
-
Publication number: 20110288169Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.Type: ApplicationFiled: September 19, 2009Publication date: November 24, 2011Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu
-
Publication number: 20110281944Abstract: This invention provides a method for inhibiting pancreatic islet ?-cell dysfunction, comprising administering to a subject in need thereof an inhibitory effective amount of a rhein compound having the general formula (I) or a pharmaceutically acceptable salt thereof,Type: ApplicationFiled: October 18, 2010Publication date: November 17, 2011Applicant: Research Institute of Nephrology of Nanjing PLA, ChinaInventor: Zhihong Liu
-
Publication number: 20110274656Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C virus, so that it can be effectively used as a preventive or therapeutic agent for Hepatitis C.Type: ApplicationFiled: January 21, 2010Publication date: November 10, 2011Applicant: B&C Biopharm Co., Ltd.Inventors: Jong Woo Kim, Sang Wook Lee, Sang Jin Park, Jung Cheul Shin, Jae Won Yang, Jong Hwan Lim
-
Publication number: 20110275649Abstract: Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin.Type: ApplicationFiled: May 3, 2011Publication date: November 10, 2011Applicant: Palmetto Pharmaceuticals LLCInventor: Wayne H. Kaesemeyer
-
Patent number: 8053603Abstract: The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.Type: GrantFiled: December 21, 2006Date of Patent: November 8, 2011Assignee: Sunovion Pharmaceuticals Inc.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Jianguo Ma
-
Publication number: 20110269830Abstract: The present invention relates to a complex made up of at least one molecule of statin or a derivative thereof, covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one 2-methyl-buta-2-ene unit, to nanoparticles of such a complex, and to a method for preparing same, said complex and/or said nanoparticles optionally being in the form of a lyophilisate. The present invention also relates to a pharmaceutical composition including at least one complex and/or nanoparticles such as previously defined. The invention finally relates to said complex and/or to said nanoparticles for the treatment and/or prevention of hyperlipemia and hypercholesterolemia.Type: ApplicationFiled: October 28, 2009Publication date: November 3, 2011Inventors: Patrick Couvreur, Didier Desmaele, Fat'ma Zouhiri, Reddy Harivardhan Lakkireddy
-
Publication number: 20110263526Abstract: The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.Type: ApplicationFiled: April 22, 2011Publication date: October 27, 2011Applicant: PIRAMAL LIFE SCIENCES LIMITEDInventor: Apparao SATYAM
-
Publication number: 20110262561Abstract: Disclosed herein are novel protoilludane norsesquiterpenoid ester compounds isolated from mycelium of Armillaria mellea that are useful for treating tumors or proliferative diseases such as breast cancers, lung cancers, colon cancers or leukemia.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Applicant: NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINEInventors: Chien-Chih Chen, Jing-Jy Cheng, Chien-Chang Shen
-
Publication number: 20110263539Abstract: The present invention provides the use of pelorol analogs of Formula, (I) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.Type: ApplicationFiled: June 21, 2007Publication date: October 27, 2011Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Raymond Andersen, Matthew Nodwell, Alice Mui
-
Publication number: 20110251158Abstract: Described herein are methods for treating inflammatory disorders or for inhibiting the build-up of arterial plaque. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.Type: ApplicationFiled: September 16, 2010Publication date: October 13, 2011Applicant: Luna Innovations IncorporatedInventors: Christopher L. KEPLEY, Robert P. LENK, Darren K. MACFARLAND, Zhiguo ZHOU
-
Publication number: 20110244045Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.Type: ApplicationFiled: May 11, 2009Publication date: October 6, 2011Applicant: TIARA PHARMACEUTICALS ,INC.Inventors: Yadon Arad, Liang C. Dong
-
Publication number: 20110245154Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.Type: ApplicationFiled: March 11, 2011Publication date: October 6, 2011Applicants: Hemaquest Pharmaceuticals, Inc., Trustees of Boston UniversityInventors: Ronald J. Berenson, Douglas V. Faller
-
Publication number: 20110245206Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.Type: ApplicationFiled: February 23, 2011Publication date: October 6, 2011Inventors: XIN JIANG, XIAOFENG LIU, JACK GREINER, STEPHEN S. SZUCS, MELEAN VISNICK
-
Publication number: 20110245283Abstract: The invention provides methods for optimizing therapeutic efficacy for treating hypercholesterolemia in a subject having a cardiovascular disease (CVD), comprising (a) determining subject characteristics that affect the likelihood of reaching a goal level of low density lipoprotein (LDL); and (b) obtaining success probabilities of a variety of statin treatments for reaching said goal level of LDL using said subject characteristics and a multivariate model; and (c) administrating the optimal statin treatment with the highest success probability of step (b) to said subject thereby optimizing therapeutic efficacy for treating hypercholesterolemia in said subject.Type: ApplicationFiled: December 21, 2010Publication date: October 6, 2011Inventor: Glen H. Murata
-
Publication number: 20110243917Abstract: The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food.Type: ApplicationFiled: August 5, 2010Publication date: October 6, 2011Inventors: Eunji Cheong, Hee-Sup Shin, Yihong Zheng, Kyoobin Lee, Jungryun Lee, Seongwook Kim, Maryam Sanati, Sukyung Lee, Yeon-Soo Kim
-
Publication number: 20110229563Abstract: A material comprising from 30 to 80% by weight of ursolic acid, from 2 to 25% by weight of oleanolic acid and from 1 to 68% by weight of triterpenoic acids other than ursolic acid or oleanolic acid, or derivatives of any of these acids, said percentages being based on total weight of said acids or derivatives and the percentages of said acids or derivatives adding up to 100%, can be used in the prevention or treatment of hypersensitivity and/or hyper-reactivity.Type: ApplicationFiled: December 17, 2004Publication date: September 22, 2011Inventors: Frederick William Cain, Wiro Stam, Ulrike Schmid, Geoff Collins
-
Patent number: 8022104Abstract: Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.Type: GrantFiled: February 24, 2006Date of Patent: September 20, 2011Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Technion Research and Development Foundation Ltd.Inventors: Daniella Licht, Ioana Lovinger, Fanny Caciularu, Adrian Gilbert
-
Publication number: 20110218204Abstract: The present invention relates to certain novel salts of Betulinic acid derivatives, to process for preparing such compounds, to use the compounds in treating diseases or disorders mediated by HIV infection, to methods for their therapeutic use and to pharmaceutical compositions containing them.Type: ApplicationFiled: January 10, 2011Publication date: September 8, 2011Applicant: HETERO RESEARCH FOUNDATION, HETERO DRUGS LIMITEDInventors: Bandi PARTHASARADHI REDDY, Vedula MANOHAR SHARMA, Kura RATHNAKAR REDDY, Musku MADHANMOHAN REDDY
-
Publication number: 20110212994Abstract: Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.Type: ApplicationFiled: June 28, 2010Publication date: September 1, 2011Inventors: BRIAN CLEM, SUCHETA TELANG, JOHN TRENT, JASON CHESNEY, POORAN CHAND, GILLES TAPOLSKY
-
Publication number: 20110201609Abstract: The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds.Type: ApplicationFiled: June 30, 2009Publication date: August 18, 2011Applicants: H. Lee Moffitt Cancer Center & Research Institute, University of South FloridaInventors: Harshani Lawrence, Yiyu Ge, Said M. Sebti, Wayne Guida
-
Publication number: 20110201598Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells.Type: ApplicationFiled: July 14, 2009Publication date: August 18, 2011Inventors: Taranjit S. Gujral, Lois M. Mulligan, Vinay K. Singh
-
Publication number: 20110190330Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I?A or I?B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.Type: ApplicationFiled: October 13, 2009Publication date: August 4, 2011Applicant: AMGEN INC.Inventors: Sean P. Brown, Paul Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, XianYun Jiao, Sujen Lai, An-Rong Li, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang, Ming Yu, Liusheng Zhu
-
Publication number: 20110190301Abstract: Therapeutic compounds, methods, and compositions are disclosed herein for treating glaucoma and baldness in mammals. The specific compounds are described herein and are modified prostaglandin derivates.Type: ApplicationFiled: May 13, 2009Publication date: August 4, 2011Applicant: ALLERGAN, INC.Inventors: David W. Old, Vinh X. Ngo, Todd S. Gac
-
Publication number: 20110190388Abstract: Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative.Type: ApplicationFiled: May 18, 2010Publication date: August 4, 2011Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Chun-Nan Lin, Huang-Yao Tu, A-Mei Huang, Bai-Luh Wei, Kim-Hong Gan, Tzyh-Chyuan Hour, Shyh-Chyun Yang, Yeong-Shiau Pu, Shen-Jeu Won
-
Publication number: 20110190251Abstract: Disclosed herein are methods of inhibiting the build-up of arterial plaque in a subject in need thereof. These methods comprise administering to the subject in need thereof a therapeutically effective amount of fullerenes.Type: ApplicationFiled: March 3, 2009Publication date: August 4, 2011Inventors: Christopher L. Kepley, Robert P. Lenk, Stephen R. Wilson, Zhiguo Zhou
-
Publication number: 20110178111Abstract: The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called “n-3 PUFA”) as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular a cardiovascular cause and for the daily administration to patients with symptomatic heart failure (HF) for more than 3.5 years.Type: ApplicationFiled: July 23, 2009Publication date: July 21, 2011Applicants: SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A, SIXTERPHARMA S.R.L.Inventors: Claudio Cavazza, Maria Giovanna Caccia
-
Patent number: 7968596Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.Type: GrantFiled: August 24, 2006Date of Patent: June 28, 2011Assignee: Australian Biomedical Company Pty, Ltd.Inventors: Peter James Jenkins, Minnie Wu, David Shine Wu
-
Publication number: 20110151033Abstract: The present invention relates to the use of compounds of isopimarane diterpene type, e.g. obtainable as or from extracts from Orthosiphon species, especially certain enriched or purified specific compounds therefrom, as well as said compounds or extracts for use or methods of using said compounds or extracts in the management of cognitive performance; in mammals, especially humans, respectively. The isopimarane diterpene type compounds can be of the formula wherein the symbols are as defined in the description and claims.Type: ApplicationFiled: December 20, 2010Publication date: June 23, 2011Applicant: BIOTROPICS MALAYSIA BHDInventors: Matthias GEHLING, Torsten GROTHE, Joachim HANS, Philipp W. WABNITZ, Tengku Shahrir TENGKU ADNAN
-
Patent number: 7964614Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.Type: GrantFiled: June 22, 2005Date of Patent: June 21, 2011Assignee: The Brigham and Women's Hospital, Inc.Inventors: Paul Ridker, Charles H. Hennekens
-
Patent number: 7960579Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: June 25, 2004Date of Patent: June 14, 2011Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Akito Yasuhara, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
-
Patent number: 7947743Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.Type: GrantFiled: June 1, 2005Date of Patent: May 24, 2011Assignee: Les Laboratories ServierInventors: Christian De Bodinat, Elisabeth Mocaer
-
Patent number: 7947738Abstract: It is intended to provide a bicyclic ?-amino acid derivative having excellent activity as an ?2? ligand. The present invention provides a compound represented by the general formula (I): wherein R1, R2, R2?, R4, R5, R6, R7, R8, and R8? are a hydrogen atom or the like; and R3 is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or the like.Type: GrantFiled: February 26, 2010Date of Patent: May 24, 2011Assignee: Daiichi Sankyo Company, Ltd.Inventors: Kousei Shimada, Asuka Kawamura, Naohisa Arakawa, Yuki Domon
-
Publication number: 20110112053Abstract: Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods relate generally to the use of compositions that inhibit RhoA GTPase levels or activity, such as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.Type: ApplicationFiled: April 16, 2009Publication date: May 12, 2011Applicant: University of Utah Research FoundationInventors: Dean Li, Kevin Whitehead, Aubrey Chan, Nyall London, Sutip Navankasattusas
-
Publication number: 20110111021Abstract: The present invention provides a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active ingredient, and a compartment containing an HMG-CoA reductase inhibitor as a pharmacologically active ingredient, wherein one compartment is a prior-release compartment and the other compartment is a delayed-release compartment. The combination preparation of the present invention can deliver a renin inhibitor and an HMG-CoA reductase inhibitor with a time interval at a specific speed, thus reducing undesirable side-effects, improving the drug efficacy and promoting the patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndromes, cardiovascular diseases, renal diseases and the like, as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.Type: ApplicationFiled: February 23, 2009Publication date: May 12, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jaw Woon Son, Jin Wook Kim